- Home
- LXEO vs VALN Comparison
LXEO vs VALN Comparison
Compare LXEO & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | VALN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.3M | 855.8M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXEO | VALN |
|---|---|---|
| Price | $7.65 | $10.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $18.60 | $15.75 |
| AVG Volume (30 Days) | ★ 1.3M | 20.3K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $1.45 | $4.56 |
| 52 Week High | $10.99 | $12.25 |
Technical Indicators
Market Signals| Indicator | LXEO | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 63.46 |
| Support Level | $7.02 | $9.62 |
| Resistance Level | $10.75 | $10.37 |
| Average True Range (ATR) | 0.84 | 0.29 |
| MACD | -0.24 | 0.06 |
| Stochastic Oscillator | 18.70 | 95.31 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.